Bone bonding in bioactive glass ceramics combined with a new synthesized agent TAK-778.
We studied the stimulatory effects of TAK-778, a new synthetic 3-benzothiepin derivative that promotes osteoblast differentiation, in the bonding of bone to bioactive glass ceramic implants in rabbit tibiae. Smooth-surfaced, rectangular plates (15 x 10 x 2 mm) made of apatite-wollastonite-containing glass ceramic were implanted bilaterally into the proximal metaphyses of rabbit tibiae. Sustained-release microcapsules containing TAK-778 were packed into the medullary cavity in one limb and untreated microcapsules were packed into the contralateral limb to serve as a paired control. At 4, 8, and 16 weeks after implantation, bonding at the bone/implant interfaces was evaluated using a detaching test and histological examination of undecalcified specimens. The tensile failure load increased during weeks 4 to 16 in both groups; the tensile failure load in the TAK-778-treated group was significantly greater than that in the control group at each interval after implantation. Histologically, the TAK-778-treated specimens showed greater active new bone formation mainly in the medullary cavity and more extensive bonding between the implant and bone than the untreated specimens. The results of this study suggest that adding the bone formation-promoting TAK-778 to bioactive glass ceramic implants may significantly accelerate bone apposition to the implants and improve the bonding process at the interface. This would help to establish earlier and stronger bonding of orthopedic ceramic implants to the surrounding bone tissue.
Kato
H
H
Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
Neo
M
M
Tamura
J
J
Nakamura
T
T
D000818:Animals; D001582:Benzothiepins / Q000494:pharmacology*; D001672:Biocompatible Materials; D018786:Bone Substitutes; D002516:Ceramics / Q000737:chemistry; D004337:Drug Carriers; D019544:Equipment Failure Analysis; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D008863:Microspheres; D016348:Osseointegration; D010012:Osteogenesis; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D019736:Prostheses and Implants; D011817:Rabbits; D013977:Tibia / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D013997:Time Factors
D001582:Benzothiepins; D001672:Biocompatible Materials; D018786:Bone Substitutes; D004337:Drug Carriers; D011108:Polymers; C120450:TAK 778; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid